(FOMX proxy) Stanley Hirsch, D.Phil. has served as our director since February 2005 and as chairman of the Board since May 2016. Dr. Hirsch has over 30 years of experience in executive positions, including director of business development for a privately held group of healthcare companies. He has also served as general manager of two diagnostics development companies. Dr. Hirsch has served as Chief Executive Officer of FuturaGene Ltd. and its predecessor company CBD Technologies Ltd., since 1995, and has also held the position of General Manager of Portman Pharmaceutical Industries. Since the acquisition of FuturaGene Plc by Suzano Pulp and Paper, a Brazilian industrial public corporation in July 2010, he has held a position equivalent to a vice president at Suzano. Dr. Hirsch currently serves as chairman of the board of directors of OWC Pharmaceutical Research Corp, a position he has held since July 2017. Dr. Hirsch holds a D. Phil. in Cell Biology and Immunology from Oxford University, England.
-----------
OWC Pharmaceutical Research (OWCP) - is years away from a product. But based on what the FDA is saying in the US, if they make companies trial the cannabis products, then OWCP will be a step ahead. However it will need tons of funds and dilution. But the politicians want to legalize cannabis asap.
If the FDA splits the products. In other words, make medical improvement claimers, prove it, then OWCP could take off.
Market Data 
Markets 
AI
